Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer | Science Translational Medicine
Sequential therapy of PARP and WEE1 inhibitors reduces T cell DNA damage and enhances antitumor immunity compared with mono- and concurrent therapy.
